PHAR - Pharming Group to report second quarter and first half 2023 financial results on August 3

PR Newswire

LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30 , on Thursday, August 3, 2023 .

Pharming will host a presentation for analysts and investors at 13:30 CEST / 07:30 EDT on August 3, 2023 .

Dial in details for the presentation are detailed below.

Webcast Link:
https://webcast.openbriefing.com/pharming1h23/

Conference Call Dial-in Details:
Netherlands : +31 85 888 7233
United States (Local): +1 646 664 1960
United Kingdom (Local): +44 20 3936 2999
Global Dial-In Numbers
Access Code: 760288

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands , and has employees around the globe who serve patients in over 30 markets in North America , Europe , the Middle East , Africa , and Asia-Pacific .

For more information, visit www.pharming.com and find us on LinkedIn .

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson , Investor Relations & Corporate Communications Manager
E: investor@pharming. com

FTI Consulting, London, UK
Victoria Foster Mitchell / Alex Shaw /Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring. nl

SOURCE Pharming Group N.V.